Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Recommendation of “Hold” from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received a consensus rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $19.33.

Several analysts have weighed in on ENTA shares. StockNews.com downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, April 6th. JPMorgan Chase & Co. cut their target price on Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Thursday, February 8th.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $12.92 on Friday. Enanta Pharmaceuticals has a 12-month low of $8.08 and a 12-month high of $37.75. The firm has a market capitalization of $273.34 million, a P/E ratio of -1.97 and a beta of 0.47. The business has a 50 day simple moving average of $14.85 and a 200 day simple moving average of $11.81.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative net margin of 187.77% and a negative return on equity of 60.38%. The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Research analysts anticipate that Enanta Pharmaceuticals will post -4.9 EPS for the current fiscal year.

Institutional Trading of Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ENTA. Nisa Investment Advisors LLC raised its stake in shares of Enanta Pharmaceuticals by 417.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,281 shares in the last quarter. Clearstead Advisors LLC acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth $57,000. Quantbot Technologies LP grew its holdings in shares of Enanta Pharmaceuticals by 2,300.0% in the 3rd quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,900 shares during the last quarter. Sherbrooke Park Advisers LLC acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth $113,000. Finally, Laurion Capital Management LP acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth $126,000. Institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.